Pacific Biosciences of California Inc (PACB) Company Profile & Statistics

Pacific Biosciences of California Inc
PACB
(Nasdaq - US)
Closed
1.77
+0.05 (+2.62%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
1.74
High
1.83
Low
1.70

About Pacific Biosciences of California Inc

CEO

Christian O. Henry

Headquarters

1305 o'brien drive

menlo park, ca 94025, united states

Auditor

Ernst & Young LLP

Employees

796

Share Holders

Website

www.pacb.com

Industry

medical specialties

Sector

health technology

Company Overview

Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved.

Pacific Biosciences of California Inc Statistics

Valuation Measures

Market Capitalization ²	483.36M
Enterprise Value	1.30B
Enterprise Value/EBITDA (ttm)	-4.72
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	1.03
Price to Sales (ttm)	2.72
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	21.75%
Operating Margin (ttm)	-141.58%
Profit Margin (ttm)	-243.80%
Return on Equity (ttm)	-42.71%
Return on Invested Capital (ttm)	-27.24%
Return on Assets (ttm)	-15.38%

Income Statement

Revenue (ttm)	173.15M
Revenue Per Share (ttm)	0.63
Gross Profit (ttm)	36.80M
EBITDA (ttm)³	-274.95M
Net Income Avi to Common (ttm)	-394.24M
Diluted EPS (ttm)	-1.46

Share Statistics

Beta (5Y Monthly)	2.01
52-Week Change	-79.43%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	273.86M
Dividend Yield	0.00%
Float ⁴	267.29M
% Held by Insiders	2.40%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	471.84M
Total Cash Per Share (mrq)	1.72
Total Debt (mrq)	893.14M
Total Debt/Equity (mrq)	197.11%
Current Ratio (mrq)	9.74%
Quick Ratio (mrq)	8.64%
Book Value Per Share (mrq)	1.65

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.64
Free Cash Flow (ytd)	-179.98M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Pacific Biosciences of California Inc

Trade With A Regulated Broker